To include your compound in the COVID-19 Resource Center, submit it here.

Insmed in-licenses DPP-1 inhibitor from AstraZeneca

AstraZeneca plc (LSE:AZN; NYSE:AZN) granted pulmonary disease company Insmed Inc. (NASDAQ:INSM) exclusive, worldwide rights to

Read the full 158 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE